Currently out of the existing stock ratings of Silvan Tuerkcan, 138 are a BUY (98.57%), 2 are a HOLD (1.43%).

Silvan Tuerkcan

Work Performance Price Targets & Ratings Chart

Analyst Silvan Tuerkcan, currently employed at JMP, carries an average stock price target met ratio of 46.91% that have a potential upside of 77.24% achieved within 184 days.

Silvan Tuerkcan’s has documented 273 price targets and ratings displayed on 22 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on BNTC, Benitec Biopharma Ltd ADR at 24-Sep-2025.

Wall Street Analyst Silvan Tuerkcan

Analyst best performing recommendations are on VOR (VOR BIOPHARMA).
The best stock recommendation documented was for VOR (VOR BIOPHARMA) at 5/9/2025. The price target of $6 was fulfilled within 133 days with a profit of $5.85 (3900%) receiving and performance score of 293.23.

Average potential price target upside

of $82.32 (57.97%) on MNDY (MONDAY.COM LTD).
of $30.05 (57.3%) on GBIO (GENERATION BIO CO).
of $16.95 (26.69%) on CRSP (CRISPR THERAPEUTICS AG).

EXEL Exelixis LOGC LogicBio Therapeutics MGNX MacroGenics NTLA Intellia Therapeutics RLAY Relay Therapeutics TPTX Turning Point Therapeutics TSHA Taysha Gene Therapies CLLS Cellectis SA GBIO Generation Bio Co MRTX Mirati Ther SGEN Seagen CRSP Crispr Therapeutics AG VOR Vor Biopharma CNST Constellation Pharmaceuticals TERN Terns Pharmaceuticals BNTC Benitec Biopharma Ltd ADR MNDY Monday.Com Ltd JSPR Jasper Therapeutics ELEV Elevation Oncology ACRV Acrivon Therapeutics, Common Stock ENGN enGene Holdings Common Stock NTBL Notable Labs

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Robert Burns (HC WAINWRIGHT)